{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:57:21Z","timestamp":1778767041143,"version":"3.51.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s11523-024-01093-6","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T12:14:50Z","timestamp":1726661690000},"page":"965-979","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of Drug\u2013Drug Interaction Potential of Talquetamab, a T-Cell-Redirecting GPRC5D\u00a0\u00d7\u00a0CD3 Bispecific Antibody, as a Result of Cytokine Release Syndrome in Patients with Relapsed\/Refractory Multiple Myeloma in MonumenTAL-1, Using a Physiologically Based Pharmacokinetic Model"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1974-1170","authenticated-orcid":false,"given":"Marie-Emilie","family":"Willemin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jue","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandi W.","family":"Hilder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tara","family":"Masterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaszianne","family":"Tolbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Renaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Heuck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colleen","family":"Kane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loeckie","family":"De Zwart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzette","family":"Girgis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuewen","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Ouellet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,16]]},"reference":[{"issue":"2","key":"1093_CR1","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188\u201395.","journal-title":"Blood"},{"issue":"7","key":"1093_CR2","doi-asserted-by":"publisher","first-page":"923","DOI":"10.2174\/138920012802138589","volume":"13","author":"S Dallas","year":"2012","unstructured":"Dallas S, Sensenhauser C, Batheja A, Singer M, Markowska M, Zakszewski C, et al. De-risking bio-therapeutics for possible drug interactions using cryopreserved human hepatocytes. Curr Drug Metab. 2012;13(7):923\u20139.","journal-title":"Curr Drug Metab"},{"issue":"5","key":"1093_CR3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2165\/11319980-000000000-00000","volume":"49","author":"JI Lee","year":"2010","unstructured":"Lee JI, Zhang L, Men AY, Kenna LA, Huang SM. CYP-mediated therapeutic protein\u2013drug interactions: clinical findings, proposed mechanisms and regulatory implications. Clin Pharmacokinet. 2010;49(5):295\u2013310.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"1093_CR4","doi-asserted-by":"publisher","first-page":"756","DOI":"10.3390\/bios12090756","volume":"12","author":"R Lei","year":"2022","unstructured":"Lei R, Arain H, Obaid M, Sabhnani N, Mohan C. Ultra-sensitive and semi-quantitative vertical flow assay for the rapid detection of interleukin-6 in inflammatory diseases. Biosensors (Basel). 2022;12(9):756.","journal-title":"Biosensors (Basel)"},{"issue":"6","key":"1093_CR5","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1111\/cts.13507","volume":"16","author":"Y Yu","year":"2023","unstructured":"Yu Y, Henrich C, Wang D. Assessment of the drug-drug interaction potential for therapeutic proteins with pro-inflammatory activities. Clin Transl Sci. 2023;16(6):922\u201336.","journal-title":"Clin Transl Sci"},{"issue":"6","key":"1093_CR6","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1002\/cpt.2814","volume":"113","author":"DE Coutant","year":"2023","unstructured":"Coutant DE, Boulton DW, Dahal UP, Deslandes A, Grimaldi C, Pereira JNS, et al. Therapeutic protein drug interactions: a white paper from the international consortium for innovation and quality in pharmaceutical development. Clin Pharmacol Ther. 2023;113(6):1185\u201398.","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"1093_CR7","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1124\/dmd.113.052225","volume":"41","author":"R Evers","year":"2013","unstructured":"Evers R, Dallas S, Dickmann LJ, Fahmi OA, Kenny JR, Kraynov E, et al. Critical review of preclinical approaches to investigate cytochrome p450-mediated therapeutic protein drug\u2013drug interactions and recommendations for best practices: a white paper. Drug Metab Dispos. 2013;41(9):1598\u2013609.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"1093_CR8","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1054\/jcaf.2002.127773","volume":"8","author":"RF Frye","year":"2002","unstructured":"Frye RF, Schneider VM, Frye CS, Feldman AM. Plasma levels of TNF-alpha and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure. J Card Fail. 2002;8(5):315\u20139.","journal-title":"J Card Fail"},{"issue":"5","key":"1093_CR9","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/clpt.2011.35","volume":"89","author":"C Schmitt","year":"2011","unstructured":"Schmitt C, Kuhn B, Zhang X, Kivitz AJ, Grange S. Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2011;89(5):735\u201340.","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"1093_CR10","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1002\/jcph.561","volume":"55","author":"Y Zhuang","year":"2015","unstructured":"Zhuang Y, de Vries DE, Xu Z, Marciniak SJ Jr, Chen D, Leon F, et al. Evaluation of disease-mediated therapeutic protein\u2013drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach. J Clin Pharmacol. 2015;55(12):1386\u201394.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"1093_CR11","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1177\/2040620716653745","volume":"7","author":"S Sarosiek","year":"2016","unstructured":"Sarosiek S, Shah R, Munshi NC. Review of siltuximab in the treatment of multicentric Castleman\u2019s disease. Ther Adv Hematol. 2016;7(6):360\u20136.","journal-title":"Ther Adv Hematol"},{"key":"1093_CR12","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration. Drug\u2013drug interaction assessment for therapeutic proteins: guidance for industry. Available from https:\/\/www.fda.gov\/media\/140909\/download. Accessed 25 April 2024."},{"key":"1093_CR13","unstructured":"European Medicines Agency, Committee for Human Medicinal Products (CHMP). Guideline on the investigation of drug interactions. Available from https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-drug-interactions-revision-1_en.pdf. Accessed 25 April 2024."},{"issue":"3","key":"1093_CR14","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/cpt.37","volume":"97","author":"HM Jones","year":"2015","unstructured":"Jones HM, Chen Y, Gibson C, Heimbach T, Parrott N, Peters SA, et al. Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective. Clin Pharmacol Ther. 2015;97(3):247\u201362.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1093_CR15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/cpt.1013","volume":"104","author":"M Shebley","year":"2018","unstructured":"Shebley M, Sandhu P, Emami Riedmaier A, Jamei M, Narayanan R, Patel A, et al. Physiologically based pharmacokinetic model qualification and reporting procedures for regulatory submissions: a consortium perspective. Clin Pharmacol Ther. 2018;104(1):88\u2013110.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1093_CR16","doi-asserted-by":"publisher","first-page":"508","DOI":"10.3390\/ph15050508","volume":"15","author":"K Haraya","year":"2022","unstructured":"Haraya K, Tsutsui H, Komori Y, Tachibana T. Recent advances in translational pharmacokinetics and pharmacodynamics prediction of therapeutic antibodies using modeling and simulation. Pharmaceuticals (Basel). 2022;15(5):508.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"2","key":"1093_CR17","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/clpt.2013.79","volume":"94","author":"KK Machavaram","year":"2013","unstructured":"Machavaram KK, Almond LM, Rostami-Hodjegan A, Gardner I, Jamei M, Tay S, et al. A physiologically based pharmacokinetic modeling approach to predict disease\u2013drug interactions: suppression of CYP3A by IL-6. Clin Pharmacol Ther. 2013;94(2):260\u20138.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1093_CR18","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/cts.13164","volume":"15","author":"L Wang","year":"2022","unstructured":"Wang L, Chen Y, Zhou W, Miao X, Zhou H. Utilization of physiologically-based pharmacokinetic model to assess disease-mediated therapeutic protein\u2013disease\u2013drug interaction in immune-mediated inflammatory diseases. Clin Transl Sci. 2022;15(2):464\u201376.","journal-title":"Clin Transl Sci"},{"issue":"3","key":"1093_CR19","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1002\/cpt.2402","volume":"111","author":"F Stader","year":"2022","unstructured":"Stader F, Battegay M, Sendi P, Marzolini C. Physiologically based pharmacokinetic modelling to investigate the impact of the cytokine storm on CYP3A drug pharmacokinetics in COVID-19 patients. Clin Pharmacol Ther. 2022;111(3):579\u201384.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1093_CR20","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1208\/s12248-016-9890-5","volume":"18","author":"X Jiang","year":"2016","unstructured":"Jiang X, Zhuang Y, Xu Z, Wang W, Zhou H. Development of a physiologically based pharmacokinetic model to predict disease-mediated therapeutic protein\u2013drug interactions: modulation of multiple cytochrome P450 enzymes by interleukin-6. AAPS J. 2016;18(3):767\u201376.","journal-title":"AAPS J"},{"issue":"1","key":"1093_CR21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/psp4.12730","volume":"11","author":"C Lenoir","year":"2022","unstructured":"Lenoir C, Niederer A, Rollason V, Desmeules JA, Daali Y, Samer CF. Prediction of cytochromes P450 3A and 2C19 modulation by both inflammation and drug interactions using physiologically based pharmacokinetics. CPT Pharmacometr Syst Pharmacol. 2022;11(1):30\u201343.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"11","key":"1093_CR22","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1634\/theoncologist.2018-0179","volume":"23","author":"ED Pulte","year":"2018","unstructured":"Pulte ED, Vallejo J, Przepiorka D, Nie L, Farrell AT, Goldberg KB, et al. FDA supplemental approval: blinatumomab for treatment of relapsed and refractory precursor B-cell acute lymphoblastic leukemia. Oncologist. 2018;23(11):1366\u201371.","journal-title":"Oncologist"},{"issue":"9","key":"1093_CR23","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/psp4.12003","volume":"4","author":"Y Xu","year":"2015","unstructured":"Xu Y, Hijazi Y, Wolf A, Wu B, Sun YN, Zhu M. Physiologically based pharmacokinetic model to assess the influence of blinatumomab-mediated cytokine elevations on cytochrome P450 enzyme activity. CPT Pharmacometr Syst Pharmacol. 2015;4(9):507\u201315.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"3","key":"1093_CR24","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/psp4.13091","volume":"13","author":"N Djebli","year":"2024","unstructured":"Djebli N, Parrott N, Jaminion F, O\u2019Jeanson A, Guerini E, Carlile D. Evaluation of the potential impact on pharmacokinetics of various cytochrome P450 substrates of increasing IL-6 levels following administration of the T-cell bispecific engager glofitamab. CPT Pharmacometr Syst Pharmacol. 2024;13(3):396\u2013409.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"2","key":"1093_CR25","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/psp4.13073","volume":"13","author":"Y Chen","year":"2024","unstructured":"Chen Y, Ma F, Jones N, Deng R, Li C, Li CC. Assessment of CYP3A-mediated drug interaction via cytokine (IL-6) elevation for mosunetuzumab using physiologically-based pharmacokinetic modeling. CPT Pharmacometr Syst Pharmacol. 2024;13(2):234\u201346.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"key":"1093_CR26","unstructured":"Columvi\u2122 (glofitamab-gxbm) prescribing information. Genentech, Inc.; 2023. Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761309s000lbl.pdf. Accessed 19 March 2024."},{"key":"1093_CR27","unstructured":"Lunsumio\u2122 (mosunetuzumab-axgb) prescribing information. Genentech, Inc.; 2022. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761263s000lbl.pdf. Accessed 19 March 2024."},{"key":"1093_CR28","unstructured":"Tecvayli\u2122 (teclistamab-cqyv) prescribing information. Janssen Biotech, Inc.; 2024. Available from https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/TECVAYLI-pi.pdf. Accessed 2 May 2024."},{"key":"1093_CR29","unstructured":"European Medicines Agency. Tecvayli\u2122 (teclistamab). Summary of product characteristics. Available from https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tecvayli-epar-product-information_en.pdf. Accessed 2 May 2024."},{"issue":"7","key":"1093_CR30","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/psp4.13144","volume":"13","author":"M-E Willemin","year":"2024","unstructured":"Willemin E-M, Ling SXW, De Zwart L, Wu LS, Miao X, Verona R, et al. Evaluating drug interaction potential from cytokine release syndrome using a physiologically based pharmacokinetic model: a case study of teclistamab. CPT Pharmacometr Syst Pharmacol. 2024;13(7):1117\u201329.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"8","key":"1093_CR31","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","volume":"5","author":"CPM Verkleij","year":"2021","unstructured":"Verkleij CPM, Broekmans MEC, van Duin M, Frerichs KA, Kuiper R, de Jonge AV, et al. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv. 2021;5(8):2196\u2013215.","journal-title":"Blood Adv"},{"key":"1093_CR32","unstructured":"Talvey\u2122 (talquetamab-tgvs) prescribing information. Janssen Biotech; 2023. Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761342s000lbl.pdf. Accessed 29 November 2024."},{"key":"1093_CR33","unstructured":"European Medicines Agency. Talvey\u2122 (talquetamab). Available from https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/talvey. Accessed 29 November 2023."},{"key":"1093_CR34","unstructured":"Schinke C, Touzeau C, Minnema M, van de Donk N, Rodr\u00edguez-Otero P, Mateos M, et al. Pivotal phase 2 MonumenTAL-1 results of talquetamab, a GPRC5D\u00d7CD3 bispecific antibody, for relapsed\/refractory multiple myeloma. Presented at American Society of Clinical Oncology (ASCO) Annual Meeting; June 2\u20136, 2023; Chicago, IL."},{"key":"1093_CR35","unstructured":"Chari A, Touzeau C, Schinke C, Minnema M, Berdega J, Oriol A, et al. Talquetamab, a G protein-coupled receptor family C group 5 member D \u00d7 CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma: phase 1\/2 results from MonumenTAL-1. Presented at American Society of Hematology (ASH) Annual Meeting; 10\u201313 December, 2022; New Orleans, LA."},{"issue":"24","key":"1093_CR36","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk N, Rodriguez-Otero P, et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387(24):2232\u201344.","journal-title":"N Engl J Med"},{"issue":"18","key":"1093_CR37","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","volume":"117","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the international myeloma workshop consensus panel 1. Blood. 2011;117(18):4691\u20135.","journal-title":"Blood"},{"issue":"8","key":"1093_CR38","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328\u201346.","journal-title":"Lancet Oncol"},{"key":"1093_CR39","unstructured":"European Medicines Agency. Guideline on the reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation. Available from https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-reporting-physiologically-based-pharmacokinetic-pbpk-modelling-and-simulation_en.pdf. Accessed 20 March 2024."},{"issue":"8","key":"1093_CR40","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1124\/dmd.111.038679","volume":"39","author":"LJ Dickmann","year":"2011","unstructured":"Dickmann LJ, Patel SK, Rock DA, Wienkers LC, Slatter JG. Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture. Drug Metab Dispos. 2011;39(8):1415\u201322.","journal-title":"Drug Metab Dispos"},{"issue":"23","key":"1093_CR41","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMra2026131","volume":"383","author":"DC Fajgenbaum","year":"2020","unstructured":"Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020;383(23):2255\u201373.","journal-title":"N Engl J Med"},{"key":"1093_CR42","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2147\/TCRM.S150524","volume":"15","author":"LL Riegler","year":"2019","unstructured":"Riegler LL, Jones GP, Lee DW. Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy. Ther Clin Risk Manage. 2019;15:323\u201335.","journal-title":"Ther Clin Risk Manage"},{"issue":"1","key":"1093_CR43","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen A, G\u00f6del P, Subklewe M, Stemmler HJ, Schl\u00f6\u00dfer HA, Schlaak M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"1093_CR44","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk N, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495\u2013505.","journal-title":"N Engl J Med"},{"issue":"3","key":"1093_CR45","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1208\/s12248-019-0309-y","volume":"21","author":"KK Machavaram","year":"2019","unstructured":"Machavaram KK, Endo-Tsukude C, Terao K, Gill KL, Hatley OJ, Gardner I, et al. Simulating the impact of elevated levels of interleukin-6 on the pharmacokinetics of various CYP450 substrates in patients with neuromyelitis optica or neuromyelitis optica spectrum disorders in different ethnic populations. AAPS J. 2019;21(3):42.","journal-title":"AAPS J"},{"issue":"10301","key":"1093_CR46","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","volume":"398","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Garfall AL, van de Donk N, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021;398(10301):665\u201374.","journal-title":"Lancet"},{"issue":"10","key":"1093_CR47","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1124\/dmd.122.000926","volume":"50","author":"KF Chen","year":"2022","unstructured":"Chen KF, Jones HM, Gill KL. Physiologically based pharmacokinetic modeling to predict drug-biologic interactions with cytokine modulators: are these relevant and is interleukin-6 enough? Drug Metab Dispos. 2022;50(10):1322\u201331.","journal-title":"Drug Metab Dispos"},{"key":"1093_CR48","unstructured":"Center for Drug Evaluation and Research. Multi-discipline review: application number: 761342Orig1s000. 2023."},{"key":"1093_CR49","unstructured":"Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s): application number: 125557Orig1s000. 2014."},{"key":"1093_CR50","unstructured":"Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s): application number: 761263Orig1s000. 2022."},{"key":"1093_CR51","unstructured":"Center for Drug Evaluation and Research. Multi-discipline review: application number: 761309Orig1s000. 2023."},{"key":"1093_CR52","unstructured":"Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s): application number: 761291Orig1s000. 2022."},{"issue":"7","key":"1093_CR53","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/psp4.13185","volume":"13","author":"X Zhang","year":"2024","unstructured":"Zhang X, Zhao P. Is PBPK useful to inform product label on managing clinically significant drug interactions mediated by cytokine release syndrome? CPT Pharmacometr Syst Pharmacol. 2024;13(7):1083\u20137.","journal-title":"CPT Pharmacometr Syst Pharmacol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01093-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-024-01093-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01093-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T05:06:55Z","timestamp":1731474415000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-024-01093-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,16]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1093"],"URL":"https:\/\/doi.org\/10.1007\/s11523-024-01093-6","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,16]]},"assertion":[{"value":"20 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was funded by Janssen Research & Development and medical writing support was funded by Janssen Global Services.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"M-EW is employed by and has stock\/other ownership interests in Janssen. JG is employed by Janssen at the time of the analysis and has stock\/other ownership interests in Janssen. BWH is employed by Janssen Oncology and has stock\/other ownership interests in Johnson & Johnson\/Janssen. TM is employed by Janssen at the time of the analysis and has stock\/other ownership interests in Janssen. JT is employed by Johnson & Johnson, has stock\/other ownership interests in Johnson & Johnson, and has received research funding from Janssen Research & Development. TR is employed by Janssen Oncology and has stock\/other ownership interests in Johnson & Johnson\/Janssen. CH is employed by Janssen at the time of the analysis and has stock\/other ownership interests in Janssen. CK is employed by Janssen at the time of the analysis and has stock\/other ownership interests in Janssen. LDZ is employed by Janssen and has stock\/other ownership interests in Janssen. SG is employed by Janssen at the time of the analysis, has stock\/other ownership interests in Bristol Myers Squibb, Janssen, and Jazz Pharmaceuticals, and holds patents with Johnson & Johnson. XM is employed by Janssen at the time of the analysis and has stock\/other ownership interests in Janssen. DO is employed by and has stock\/other ownership interests in Janssen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets generated and\/or analyzed during the current study are not publicly available but are available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at . As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at .","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Sharing"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"M-EW: wrote the manuscript, designed the research, performed the research, analyzed the data, and contributed significantly to the manuscript review and editing. JG: designed the research, performed the research, contributed to the data acquisition and interpretation, and writing (review and editing). BWH: contributed to conceptualization, data acquisition, investigation, methodology, validation, and writing (review and editing). TM: contributed to conceptualization, data acquisition, investigation, methodology, validation, and writing (review and editing). JT: contributed to conceptualization, data acquisition, investigation, methodology, validation, and writing (review and editing). TR: contributed to conceptualization, data acquisition, investigation, methodology, validation, and writing (review and editing). CH: contributed to conceptualization, data acquisition, investigation, methodology, validation, and writing (review and editing). CK: contributed to conceptualization, data acquisition, investigation, methodology, validation, and writing (review and editing). LDZ: designed the research, performed the research, analyzed the data, and contributed to writing (review and editing). SG: designed the research, contributed to the data analysis and interpretation, and writing (review and editing). XM: designed the research, analyzed the data, contributed to the data analysis and interpretation, and writing (review and editing). DO: designed the research, performed the research, analyzed the data, and contributed to writing (review and editing).","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}